

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

BLACK BORDERS

TEXT CUT OFF AT TOP, BOTTOM OR SIDES

- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB	c5 same antibod\$.clm.	12	<u>L4</u>
USPT	c5 same antibod\$.clm.	11	<u>L3</u>
USPT	c5.clm.	1008	<u>L2</u>
USPT,PGPB,JPAB,EPAB,DWPI	(c5) same (antibod\$) same (treat\$ or therap\$ or prevent\$ or inhibit\$ or suppress\$ or block\$ or antagoni\$)	214	<u>L1</u>

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

Search Results -

Term	Documents
C5.USPT,PGPB.	21659
C5S.USPT,PGPB.	8
ANTIBOD\$	0
ANTIBOD.USPT,PGPB.	276
ANTIBODAY.USPT,PGPB.	1
ANTIBODEES.USPT,PGPB.	1
ANTIBODEIS.USPT,PGPB.	1
ANTIBODES.USPT,PGPB.	54
ANTIBODES:.USPT,PGPB.	1
ANTIBODEY.USPT,PGPB.	1
.....	
ANTIBOD\$(ANTIBODY-1353).CLM.	pickup term
(C5 SAME ANTIBOD\$.CLM.).USPT,PGPB.	12

[There are more results than shown above. Click here to view the entire set.](#)

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search:

c5 same antibod\$.clm.

[Clear](#)**Search History****Today's Date: 1/19/2002**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT	c5 same antibod\$.clm.	11	<u>L3</u>
USPT	c5.clm.	1008	<u>L2</u>
USPT,PGPB,JPAB,EPAB,DWPI	(c5) same (antibod\$) same (treat\$ or therap\$ or prevent\$ or inhibit\$ or suppress\$ or block\$ or antagoni\$)	214	<u>L1</u>

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

Search Results -

Term	Documents
C5.USPT.	20976
C5S.USPT.	8
ANTIBOD\$	0
ANTIBOD.USPT.	261
ANTIBODAY.USPT.	1
ANTIBODEES.USPT.	1
ANTIBODEIS.USPT.	1
ANTIBODES.USPT.	49
ANTIBODES:.USPT.	1
ANTIBODEY.USPT.	1
.....	
ANTIBOD\$(ANTIBODY.SUB.1).CLM.	pickup term
(C5 SAME ANTIBOD\$.CLM.).USPT.	11

[There are more results than shown above. Click here to view the entire set.](#)

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search:

c5 same antibod\$.clm.

[Clear](#)**Search History****Today's Date:** 1/19/2002

Generate Collection

☐ 1. Document ID: AU 735596 B, WO 9529697 A1, AU 9524747 A, EP 758904 A1, BR 9507594 A, JP 10500289 W, KR 97702732 A, MX 9605330 A1, AU 9941042 A, US 6074642 A

Jul 12, 2001

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Treating glomerulonephritis with antibody against complement C5
component - to inhibit complement induced cell lysis

INVENTOR: EVANS, M J; MATIS, L ; MUELLER, E E ; NYE, S H ; ROLLINS, S ; ROTHER, R P ; SPRINGHORN, J P ; SQUINTO, S P ; THOMAS, T C ; WANG, Y ; WILKINS, J A

PRIORITY-DATA: 1994US-0236208 (May 2, 1994), 1999AU-0041042 (July 21, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 735596 B	July 12, 2001		000	C07K014/00
WO 9529697 A1	November 9, 1995	E	181	A61K038/36
AU 9524747 A	November 29, 1995		000	A61K038/36
EP 758904 A1	February 26, 1997	E	000	A61K038/36
BR 9507594 A	September 16, 1997		000	A61K038/36
JP 10500289 W	January 13, 1998		179	C12N015/09
KR 97702732 A	June 10, 1997		000	A61K038/36
MX 9605330 A1	February 1, 1998		000	A61K038/36
AU 9941042 A	October 28, 1999		000	A61K038/36
US 6074642 A	June 13, 2000		000	A61K039/395

INT-CL (IPC): A01K 67/027; A61K 38/00; A61K 38/36; A61K 39/00; A61K 39/395; C07H 21/04; C07K 14/00; C07K 14/47; C07K 14/75; C07K 16/00; C07K 16/06; C07K 16/18; C07K 16/36; C07K 16/46; C12N 5/10; C12N 5/20; C12N 15/02; C12N 15/09; C12N 15/10; C12N 15/13; C12N 15/63; C12P 21/02; C12P 21/08; G01N 33/53

Full	Title	CLS.1	REF.1
------	-------	-------	-------

Generate Collection

Term	Documents
5G1\$	0
5G1.DWPI,EPAB,JPAB.	5
"5G1M2.TRANSPARENT9".DWPI,EPAB,JPAB.	1
5G1-5G3.DWPI,EPAB,JPAB.	1
"5G1.1".DWPI,EPAB,JPAB.	1
C5.DWPI,EPAB,JPAB.	11539
C5S.DWPI,EPAB,JPAB.	1
(5G1\$ AND C5).JPAB,EPAB,DWPI.	1

Documents, starting with Document:

Display Format:

WEST

Generate Collection

Search Results - Record(s) 1 through 1 of 1 returned.☐ 1. Document ID: US 6074642 A

L3: Entry 1 of 1

File: USPT

Jun 13, 2000

US-PAT-NO: 6074642

DOCUMENT-IDENTIFIER: US 6074642 A

TITLE: Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis

DATE-ISSUED: June 13, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wang; Yi	Orange	CT		
Matis; Louis	Southport	CT		
Rollins; Scott	Monroe	CT		

US-CL-CURRENT: 424/145.1; 424/130.1, 424/140.1, 424/141.1, 424/152.1, 424/158.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	MMC	Draw Desc	Image

Generate Collection

Term	Documents
5G1\$	0
5G1.USPT,PGPB.	48
5G1B.USPT,PGPB.	1
5G1C.USPT,PGPB.	39
5G1CG.USPT,PGPB.	1
5G1C0.USPT,PGPB.	2
5G1C7G2C.USPT,PGPB.	2
5G1C8H.USPT,PGPB.	2
5G1G.USPT,PGPB.	1
5G1H.USPT,PGPB.	7
(5G1\$ AND C5.CLM.).USPT,PGPB.	1

There are more results than shown above. [Click here to view the entire set.](#)

Display

10

Documents, starting with Document: 1

Display Format:

CIT

Change Format

WEST☐ Generate Collection

L4: Entry 4 of 12

File: USPT

Dec 29, 1998

US-PAT-NO: 5853722

DOCUMENT-IDENTIFIER: US 5853722 A

TITLE: Use of C5-specific antibodies for reducing immune and hemostatic dysfunctions during extracorporeal circulation

DATE-ISSUED: December 29, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rollins; Scott	Monroe	CT		
Smith; Brian R.	Madison	CT		
Squinto; Stephen P.	Bethany	CT		

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE	CODE
Alexion Pharmaceuticals, Inc.	New Haven	CT			02	
Yale University	New Haven	CT			02	

APPL-NO: 8/ 575057

DATE FILED: December 21, 1995

PARENT-CASE:

This application is a continuation application of application Ser. No. 08/217,391, filed on Mar. 23, 1994 now abandoned.

INT-CL: [6] A61K 39/395, C07K 16/36

US-CL-ISSUED: 424/145.1; 424/140.1, 530/387.29, 530/389.3

US-CL-CURRENT: 424/145.1; 424/140.1, 530/388.25, 530/389.3

FIELD-OF-SEARCH: 424/130.1, 424/140.1, 424/145.1, 530/387.1, 530/388.1, 530/388.25, 530/389.1, 530/389.3

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

☐ Search Selected☐ Search ALL

PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
<input type="checkbox"/> <u>4686100</u>	August 1987	Raffin et al.	N/A
<input type="checkbox"/> <u>5135916</u>	August 1992	Sims et al.	514/21
<input type="checkbox"/> <u>5506247</u>	April 1996	Sindelar et al.	N/A

OTHER PUBLICATIONS

Harris et al. Tib Tech 11:42-45 (1993).

Wurzner et al. Complmt. inflamm 8:328-340 (1981).

Mollnes Ann Thorac Surg 52:92-7 (1991).

Bator et al. Mediators of Inflammation 2:135-141 (1993).

Videm et al. J. Thorac Cardiovasc Surg 101:654-60 (1991).

Altieri, et al., "Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: An alternative initiation of the coagulation protease cascade" Proc Natl Acad Sci USA 85:7462-7466, 1988.

Arnaout, et al. "Increased Expression of an Adhesion-Promotion Surface Glycoprotein in the Granulocytopenia of Hemodialysis" N Engl J Med 312:457-462, 1985.

Arnaout, "Structure and Function of the Leukocyte Adhesion Molecules CD11/CD18" Blood 75:1037-1050, 1990.

Aslan, et al., "The factors effecting complement activation in open heart surgery" J Cardiovasc Surg 33:754-760, 1992.

Bidstrup, et al., "Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (TrasyL0L)" J Thorac Cardiovasc Surg 973:364-372, 1989.

L. Casey, "Role of Cytokines in the Pathogenesis of Cardiopulmonary-Induced Multisystem Organ Failure" Ann Thorac Surg 56:S92-6, 1993.

Cavarocchi, et al., "Complement activation during cardiopulmonary bypass" J Thorac Cardiovasc Surg 91:252-258, 1986.

Cavarocchi, et al., "Oxygen free radical generation during cardiopulmonary bypass: correlation with complement activation" Circulation 74 (suppl III):130-133, 1986.

Chenoweth, et al., "Complement Activation during Cardiopulmonary Bypass" N Eng J Med 304:497-502 1981.

D. Chenoweth, "Anaphylatoxin Formation in Extracorporeal Circuits" Complement 3:152-165, 1986.

Chiu, et al., "Complement (C3, C4) Consumption in Cardiopulmonary Bypass, Cardioplegia, and Protamine Administration" Ann Thorac Surg 37:229-232, 1984.

Copeland, et al., "Bleeding and Anticoagulation" Ann Thorac Surg 47:88-95, 1989.

Cosgrove, et al., "Aprotinin Therapy for Reoperative Myocardial Revascularization: A Placebo-Controlled Study" Ann Thorac Surg 54:1031-38, 1992.

Dreyer, et al., "Neutrophil Accumulation in Ischemic Canine Myocardium: Insights into Time Course, Distribution, and Mechanism of Localization During Early Reperfusion" Circ 84:400-411, 1991.

Finn, et al., "Interleukin-8 release and neutrophil degranulation after pediatric cardiopulmonary bypass" J Thorac Cardiovasc Surg, 105:234-241, 1993.

Furie, et al., "E-Selectin (Endothelial-Leukocyte Adhesion Molecule-1) Is Not Required for the Migration of Neutrophils across IL--1--Stimulated Endothelium in Vitro" J Immunol 148:2395-2404, 1992.

Gillinov, et al., "Complement Inhibition With Soluble Complement Receptor Type 1 in Cardiopulmonary Bypass" Ann Thorac Surg 55:619-624, 1993.

Gillinov, et al., "Neutrophil Adhesion Molecule Expression During Cardiopulmonary Bypass with Bubble and Membrane Oxygenators" Ann Thorac Surg 56:847-853, 1993.

Gillinov, et al., "Complement and Neutrophil Activation During Cardiopulmonary Bypass: A Study in the Complement--Deficient Dog" Ann Thorac Surg 57:345-352, 1994.

Hackmann, et al. "A Trial of Desmopressin (1--Desamino--8--D--Arginine Vasopressin) to Reduce Blood Loss in Uncomplicated Cardiac Surgery" N Engl J Med 321:1437-1442, 1989.

Haslam, et al., "Complement activation during cardiopulmonary bypass" Anaesthesia, 35:22-26, 1980.

Jones, et al. "Cardiopulmonary bypass and complement activation" Anaesthesia, 37:629-633, 1982.

Kirklin, et al., "Complement and the damaging effects of cardiopulmonary bypass" J Thorac Cardiovasc Surg 86:845-857, 1983.

Levy et al., "Inflammation and cardiopulmonary bypass" Can J Anaesth 40:1009-1015, 1993.

Miyamoto, et al. "Analysis of Complement Activation Profile during Cardiopulmonary Bypass and Its Inhibition by FUT-175" ASAIO J 31:508-511, 1985.

Moat, et al. "Complement inhibition may attenuate acute lung injury after cardiopulmonary bypass in pigs" Am Rev Respir Dis 145:A845, 1992.

Moat, et al., "Humoral and Cellular Activation in a Simulated Extracorporeal Circuit" Ann Thorac Surg 56:1509-1514, 1993.

Mohr, et al., "The hemostatic effect of transfusing fresh whole blood versus platelet concentrates after cardiac operations" J. Thorac. Cardiovasc. Surg.96:530-534, 1988.

Mollnes, et al., "Identification of a Human C5 .beta.--Chain Epitope Exposed in the Native Complement Component but Concealed in the SC5b-9 Complex" Scand. J. Immunol.28:307-312, 1988.

Moongkarndi, et al., "Monoclonal antibodies against the fifth component of human complement" Immunobiol.162:397, 1982.

Moongkarndi, et al., "Immunological and functional properties of two monoclonal antibodies against human C5"0 Immunobiol.165:323, 1983.

Montz, et al., "Regulation of the Human Autologous T Cell Proliferation by Endogenously Generated C5a" Cellular Immunol.127:337-351, 1990.

Nathan, et al., "Cytokine-induced Respiratory Bur Human Neutrophils: Dependence on Extracellular Matrix Proteins and CD11/CD18 Integrins" J Cell Biol109:1341-1349, 1989.

Nilsson, et al., "Heparin-Coated Equipment Reduces Complement Activation during Cardiopulmonary Bypass in the Pig" Artif Organs14:46-48, 1990.

.O slashed.vrum, et al., "Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations" J Thorac Cardiovasc Surg.105:78-83, 1993.

Palabrica, et al., "Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P--selectin on adherent platelets" Nature359:848-851, 1992.

Parker, et al., "Changes in serum complement and immunoglobulins following cardiopulmonary bypass" Surgery71:824-827, 1972.

Rinder, et al., "Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion" Transfusion,31:409-414, 1991.

Rinder, et al, "Cardiopulmonary Bypass Induces Leukocyte-Platelet Adhesion" Blood,79:1201-1205, 1992.

Rocha, et al., "Does despmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass?" Circulation77:1319-1323, 1988.

Seghaye, et al., "Complement activation during cardiopulmonary bypass in infants and children" J Thorac Cardiovasc Surg106:978-987, 1993.

Steinberg, et al., "Cytokine and complement levels in patients undergoing cardiopulmonary bypass" J Thorac Cardiovasc Surg106:1008-1016, 1993.

Simpson, et al., "Reduction of Experimental Canine Myocardial Reperfusion Injury by a Monoclonal Antibody (Anti-Mol, Anti-CD11b) That Inhibits Leukocyte Adhesion" J Clin Invest81:624-629, 1988.

Sonntag and Stein, "Arteriopathic complications during treatment of subarachnoid hemorrhage with epsilonaminocaproic acid" J Neurosurg40:480-484, 1974.

Stanuton, et al., "Primary Structure of ICAM-1 Demonstrates Interaction between Members of the Immunoglobulin and Integrin Supergene Families" Cell52:925-933, 1988.

Staunton, et al., "Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1" Nature339:61-64, 1989.

Taggart, et al., "Endotoxemia, Complement, and White Blood Cell Activation in Cardiac Surgery: A Randomized Trial of Laxatives and Pulsatile Perfusion" Ann Thorac Surg57:376-382, 1984.

Tulunay, et al., "Complement (C3, C4) and C--reactive Protein Responses to Cardiopulmonary Bypass and Protamine Administration" Anaesth Intens Care21:50-55, 1993.

Videm, et al., "Different oxygenators for cardiopulmonary bypass lead to varying degrees of human complement activation in vitro" J. Thorac. Cardiovasc. Surg.,97:764-770, 1989.

Videm, et al., "Complement Activation with Bubble and Membrane Oxygenators in Aortocoronary Bypass Grafting" Ann Thorac Surg50:387-731, 1990.

Videm, et al., "Time for New Concepts About Measurement of Complement Activation by Cardiopulmonary Bypass" Ann Thorac Surg54:725-731, 1992.

Wachtfogel, et al., "Human neutrophil Degranulation During Extracorporeal Circulation" Blood69:324-330, 1989.

Wakefield, et al., "Absence of Complement Mediated Events after Protamine Reversal of Heparin Anticoagulation" J. Surg. Res.51:72-76, 1991.

Wenger, et al., "Loss of platelet fibrinogen receptors during clincial

cardiopulmonary bypass" J Thorac Cardiovasc Surg, 97:235-239, 1989.
Wurzner, et al., "Complement activation and depletion during LDL-apheresis by
heparin-induced extracorporeal LDL-precipitation (HELP)" European Journal of
Clinical Investigation 21:288-294, 1991.

ART-UNIT: 186

PRIMARY-EXAMINER: Feisee; Lila

ASSISTANT-EXAMINER: Gambel; Phillip

ATTY-AGENT-FIRM: Klee; Maurice M. Fidel; Seth A.

ABSTRACT:

The use of anti-C5 antibodies to reduce the dysfunction of the immune and hemostatic systems associated with extracorporeal circulation procedures, such as, cardiopulmonary bypass procedures, is disclosed. The antibodies have been found to significantly reduce complement activation, platelet activation, leukocyte activation, and platelet-leukocyte adhesion associated with such procedures.

8 Claims, 4 Drawing figures